Abstract
Although the highest levels of PPARγ expression in the body have been reported in the gastrointestinal epithelium, little is known about the physiological functions of that receptor in the gut. Moreover, there is considerable controversy concerning the effects of thiazolidinedione PPARγ agonists on the two major diseases of the gastrointestinal track: colorectal cancer and inflammatory bowel disease. We will undertake to review both historical and recently published data with a view toward summarizing what is presently known about the roles of PPARγ in both physiological and pathological processes in the gastrointestinal epithelium.
Original language | English (US) |
---|---|
Article number | 148687 |
Journal | PPAR Research |
DOIs | |
State | Published - 2008 |
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology (medical)